GPCR NewsMar 1, 20221 minGPCR Industry NewsDomain Therapeutics and Explicyte enter partnership agreement in immuno-oncologyMarch 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop first-in...